BIIBApproval•globenewswire•
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Sentiment:Positive (70)
Summary
(NASDAQ:BIIB) LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatment of 18 months
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 29, 2025 by globenewswire